ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0199

Delivery of Guideline Concordant Care in Childhood-Onset Lupus Nephritis

Alisha Akinsete1, Mangala Rajan2, Orysya Soroka2, Karen Onel3, Monika Safford2 and Iris Navarro Millan4, 1Weill Cornell Medicine/ Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, NY, 3HSS, New York, NY, 4Weill Cornell Medicine, Hospital for Special Surgery, New York, NY

Meeting: ACR Convergence 2024

Keywords: Access to care, Administrative Data, Health Services Research, Lupus nephritis, Quality Indicators

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Health Services Research – ACR/ARP Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: 50-80% of children with childhood-onset systemic lupus erythematosus (cSLE) develop lupus nephritis (LN). Children from historically marginalized communities are disproportionately affected by cSLE and LN compared to their White counterparts, with higher prevalence and more severe LN outcomes. Adherence to these LN guidelines is not consistent. This study aims to investigate differences in adherence to guideline-recommended quality indicators among pediatric patients with LN based on factors such as race/ethnicity, age, comorbidity burden, and healthcare access.

Methods: Using Medicaid via Marketscan data from 2011-2019, we identified individuals with LN between the ages of 5 and 21. Patients are required to ≥ 3 or more SLE ICD-9 or ICD-10 codes in outpatient visit claims or hospital discharge diagnosis codes at least 30 days apart and have ≥ 3 ICD-9/ICD-10 for nephritis and a procedure code for renal biopsy. Adherence to 7 LN quality indicators, were evaluated (Table 1). Multivariable analysis was performed to understand the association of race and ethnicity, comorbidities, age, and healthcare access with adherence to quality indicators.

Results: We identified 598 children with prevalent childhood-onset LN;11.5% were Hispanic 52.3% Black, 14.5% White, 7.7% Unknown, 13.9% Other. (Table 2). Adherence to quality indicators was low (HCQ use: 46%, medication toxicity CBC: 69.3% LFT: 7.8%, disease activity monitoring: 46.4%, adequate follow-up: 76.1%, use of steroid-sparing agent: 29.8%, use of ACEi or ARB: 48.7%. No significant differences were noted by race/ethnicity.  In the multivariable analysis, Black children and Other were associated with higher performance of HCQ use; RR 1.40, 95% CI (1.01-1.95) and RR 1.71, 95% CI (1.16-2.52), respectively. No other associations between race and ethnicity were noted. Older age (18-22 years old) was associated with lower performance of many quality indicators, which include HCQ use (RR 0.64, 95% CI [0.50-0.80]), disease activity surveillance labs (RR 0.66, 95% CI [ 0.56-0.78)] and ACEi/ARB use for HTN and proteinuria (RR 0.56, 95% CI [ 0.43-0.73]). Similarly, children with fewer visits in a year (1-4 visits) were associated with lower performance for HCQ use (RR 0.74, 95% CI 0.62-0.88), LFTs toxicity labs (RR 0.40, 95% CI 0.21-0.75), disease activity labs (RR 0.55, 95% CI 0.44-0.70), ACEi/ARB use (RR 0.63, 95% CI 0.52-0.76) (Table 3).

Conclusion: Our study suggests that children with prevalent LN and Medicaid coverage have poor adherence to LN quality indicators. There were no significant differences by race/ethnicity, but young adults had even lower adherence compared with younger children. Providers must include transition plans for young adults to ensure continuous quality care.

Supporting image 1

ACE/ARBS – Angiotensin-Converting Enzyme inhibitors/Angiotensin receptor blockers; DMARDs -Disease-Modifying Antirheumatic Drugs; HTN – Hypertension; UA – Urinalysis; Up/Ucr – Urine protein/Urine creatinine ratio; Cr -Creatinine; C3 – Complement 3; C4 – Complement 4; dsDNA -Double-stranded DNA; ESR – Erythrocyte Sedimentation Rate

Supporting image 2

DMARDs -Disease-Modifying Antirheumatic Drugs; HTN – Hypertension; EM – Evaluation and Management (Outpatient)

Supporting image 3

* Statistically significant p<0.05 (Bonferroni adjustment)


Disclosures: A. Akinsete: None; M. Rajan: None; O. Soroka: None; K. Onel: None; M. Safford: None; I. Navarro Millan: None.

To cite this abstract in AMA style:

Akinsete A, Rajan M, Soroka O, Onel K, Safford M, Navarro Millan I. Delivery of Guideline Concordant Care in Childhood-Onset Lupus Nephritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/delivery-of-guideline-concordant-care-in-childhood-onset-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/delivery-of-guideline-concordant-care-in-childhood-onset-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology